Vaccine description | |
---|---|
Target | SARS-CoV-2 |
Vaccine type | mRNA |
Clinical data | |
Other names | MRT5500, VAW00001 |
Routes of administration | Intramuscular |
Legal status | |
Legal status |
|
The SanofiâTranslate Bio COVID-19 vaccine, also known as MRT5500 or VAW00001, was a COVID-19 vaccine candidate developed by Sanofi Pasteur and Translate Bio. [2] [3] The development was stopped in September 2021. [4]
In June 2020, Sanofi, after lagging behind its competitors, "accelerated" the development of the vaccine via the smaller biotech firm Translate Bio, with a US$425 million partnership. [5]
Development of the vaccine halted in September 2021, with Sanofi citing the difficulty of running placebo-controlled studies with other mRNA vaccines (such as Pfizer's and Moderna's) already on the market. Despite this, the company reported "promising results" in its initial trials. [4]Sanofi has continued testing its recombinant protein vaccine, developed collaboratively with GlaxoSmithKline, to serve as a booster dose for other COVID-19 vaccines. [4]
Development | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Classes | |||||||||||
Administration | |||||||||||
Vaccines |
| ||||||||||
Inventors/ researchers | |||||||||||
Controversy | |||||||||||
Related | |||||||||||
|
This article about COVID-19 vaccines is a stub. You can help Wikipedia by expanding it. |
This article about vaccines or vaccination is a stub. You can help Wikipedia by expanding it. |
Vaccine description | |
---|---|
Target | SARS-CoV-2 |
Vaccine type | mRNA |
Clinical data | |
Other names | MRT5500, VAW00001 |
Routes of administration | Intramuscular |
Legal status | |
Legal status |
|
Part of a series on the |
COVID-19 pandemic |
---|
|
Medical response |
|
COVID-19 portal |
The SanofiâTranslate Bio COVID-19 vaccine, also known as MRT5500 or VAW00001, was a COVID-19 vaccine candidate developed by Sanofi Pasteur and Translate Bio. [2] [3] The development was stopped in September 2021. [4]
In June 2020, Sanofi, after lagging behind its competitors, "accelerated" the development of the vaccine via the smaller biotech firm Translate Bio, with a US$425 million partnership. [5]
Development of the vaccine halted in September 2021, with Sanofi citing the difficulty of running placebo-controlled studies with other mRNA vaccines (such as Pfizer's and Moderna's) already on the market. Despite this, the company reported "promising results" in its initial trials. [4]Sanofi has continued testing its recombinant protein vaccine, developed collaboratively with GlaxoSmithKline, to serve as a booster dose for other COVID-19 vaccines. [4]
Development | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Classes | |||||||||||
Administration | |||||||||||
Vaccines |
| ||||||||||
Inventors/ researchers | |||||||||||
Controversy | |||||||||||
Related | |||||||||||
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
This article about COVID-19 vaccines is a stub. You can help Wikipedia by expanding it. |
This article about vaccines or vaccination is a stub. You can help Wikipedia by expanding it. |